Држава: Канада
Језик: Енглески
Извор: Health Canada
RAMIPRIL
AURO PHARMA INC
C09AA05
RAMIPRIL
10MG
CAPSULE
RAMIPRIL 10MG
ORAL
30/100/500
Prescription
ANGIOTENSIN-CONVERTING ENZYME INHIBITORS
Active ingredient group (AIG) number: 0122858002; AHFS:
APPROVED
2012-08-24
AURO-RAMIPRIL PRODUCT MONOGRAPH PAGE 1 OF 44 PRODUCT MONOGRAPH PR AURO-RAMIPRIL Ramipril Capsules 1.25 mg, 2.5 mg, 5 mg and 10 mg BP ATC Code: C09AA05 Angiotensin Converting Enzyme Inhibitor AURO PHARMA INC. 3700 Steeles Avenue West, Suite # 402 Woodbridge, Ontario, L4L 8K8, Canada Date of Revision: January 11, 2023 Submission Control No.: 266581 AURO-RAMIPRIL PRODUCT MONOGRAPH PAGE 2 OF 44 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ...................................................... 3 SUMMARY PRODUCT INFORMATION ............................................................................ 3 INDICATIONS AND CLINICAL USE ................................................................................. 3 CONTRAINDICATIONS ..................................................................................................... 4 WARNINGS AND PRECAUTIONS ..................................................................................... 5 ADVERSE REACTIONS.....................................................................................................12 DRUG INTERACTIONS .....................................................................................................17 DOSAGE AND ADMINISTRATION ..................................................................................21 OVERDOSAGE ..................................................................................................................23 ACTION AND CLINICAL PHARMACOLOGY..................................................................24 STORAGE AND STABILITY .............................................................................................27 DOSAGE FORMS, COMPOSITION AND PACKAGING ...................................................27 PART II: SCIENTIFIC INFORMATION ........................................................................ 29 PHARMACEUTICAL INFORMATION ..............................................................................29 CLINICAL TRIALS ......................................................... Прочитајте комплетан документ